AVXL
Price
$9.57
Change
-$0.07 (-0.73%)
Updated
Sep 2, 04:11 PM (EDT)
Capitalization
828.02M
111 days until earnings call
IDYA
Price
$25.38
Change
+$0.83 (+3.38%)
Updated
Sep 2, 04:38 PM (EDT)
Capitalization
2.15B
70 days until earnings call
Interact to see
Advertisement

AVXL vs IDYA

Header iconAVXL vs IDYA Comparison
Open Charts AVXL vs IDYABanner chart's image
Anavex Life Sciences
Price$9.57
Change-$0.07 (-0.73%)
Volume$2.35K
Capitalization828.02M
IDEAYA Biosciences
Price$25.38
Change+$0.83 (+3.38%)
Volume$136
Capitalization2.15B
AVXL vs IDYA Comparison Chart in %
Loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. IDYA commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (AVXL: $9.64 vs. IDYA: $24.55)
Brand notoriety: AVXL and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 83% vs. IDYA: 64%
Market capitalization -- AVXL: $828.02M vs. IDYA: $2.15B
AVXL [@Biotechnology] is valued at $828.02M. IDYA’s [@Biotechnology] market capitalization is $2.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AVXL is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • AVXL’s TA Score: 4 bullish, 6 bearish.
  • IDYA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than AVXL.

Price Growth

AVXL (@Biotechnology) experienced а +1.15% price change this week, while IDYA (@Biotechnology) price change was -2.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +22.15%, and the average quarterly price growth was +32.80%.

Reported Earning Dates

AVXL is expected to report earnings on Dec 22, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+6.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.15B) has a higher market cap than AVXL($828M). IDYA YTD gains are higher at: -4.475 vs. AVXL (-10.242). AVXL has higher annual earnings (EBITDA): -45.88M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. AVXL (101M). AVXL has less debt than IDYA: AVXL (88.2K) vs IDYA (26.6M). IDYA has higher revenues than AVXL: IDYA (7M) vs AVXL (0).
AVXLIDYAAVXL / IDYA
Capitalization828M2.15B38%
EBITDA-45.88M-380.2M12%
Gain YTD-10.242-4.475229%
P/E RatioN/AN/A-
Revenue07M-
Total Cash101M670M15%
Total Debt88.2K26.6M0%
FUNDAMENTALS RATINGS
AVXL vs IDYA: Fundamental Ratings
AVXL
IDYA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
8270
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4654
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVXL's Valuation (57) in the Biotechnology industry is in the same range as IDYA (61) in the null industry. This means that AVXL’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (70) in the null industry is in the same range as AVXL (82) in the Biotechnology industry. This means that IDYA’s stock grew similarly to AVXL’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as AVXL (97) in the Biotechnology industry. This means that IDYA’s stock grew similarly to AVXL’s over the last 12 months.

AVXL's Price Growth Rating (46) in the Biotechnology industry is in the same range as IDYA (54) in the null industry. This means that AVXL’s stock grew similarly to IDYA’s over the last 12 months.

AVXL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that AVXL’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLIDYA
RSI
ODDS (%)
Bullish Trend 5 days ago
74%
Bearish Trend 5 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
87%
Bearish Trend 5 days ago
75%
Momentum
ODDS (%)
Bearish Trend 5 days ago
82%
Bullish Trend 5 days ago
76%
MACD
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 5 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
84%
Bearish Trend 5 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 27 days ago
79%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 5 days ago
80%
Bullish Trend 5 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMJPX12.070.07
+0.58%
Goldman Sachs Real Estate Securities P
HDGFX35.53-0.04
-0.11%
Hartford Dividend and Growth F
SEVAX38.98-0.07
-0.18%
NAA SMid Cap Value A
FHJTX44.31-0.25
-0.56%
Fidelity Advisor Europe C
NBGTX32.14-0.34
-1.05%
Neuberger Berman Large Cap Growth Tr

AVXL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with PLRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
+4.56%
PLRX - AVXL
47%
Loosely correlated
+1.23%
TENX - AVXL
45%
Loosely correlated
+1.01%
RXRX - AVXL
42%
Loosely correlated
-3.39%
MGNX - AVXL
40%
Loosely correlated
+4.12%
IDYA - AVXL
37%
Loosely correlated
-1.52%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NRIX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.52%
NRIX - IDYA
61%
Loosely correlated
-0.74%
SYRE - IDYA
61%
Loosely correlated
-1.38%
IMNM - IDYA
60%
Loosely correlated
-3.94%
CGON - IDYA
60%
Loosely correlated
+0.39%
XENE - IDYA
58%
Loosely correlated
+0.28%
More